Paper29697201
Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
Wang X and 1 other. Thorac Cancer, 2018. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. Papers, record 29697201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29697201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Cisplatin | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| MicroRNAs | Major topic |
| Nuclear Proteins | Major topic |
| Proto-Oncogene Proteins | Major topic |
| Cell Cycle Proteins | |
| Cell Line, Tumor | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| MCF-7 Cells | |
| Tumor Suppressor Protein p53 |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16518375 | Targeting multidrug resistance in cancer. | Nat Rev Drug Discov | 2006 | https://conductscience.org/library/papers/16518375 | PubMed |
| 2 | 25717219 | Cancer statistics: updated cancer burden in China. | Chin J Cancer Res | 2015 | https://conductscience.org/library/papers/25717219 | PubMed |
| 3 | 23893241 | miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. | Oncogene | 2014 | https://conductscience.org/library/papers/23893241 | PubMed |
| 4 | 9703789 | Chemotherapy resistance in breast cancer. | Anticancer Res | 1998 | https://conductscience.org/library/papers/9703789 | PubMed |
| 5 | 8895579 | MDMX: a novel p53-binding protein with some functional properties of MDM2. | EMBO J | 1996 | https://conductscience.org/library/papers/8895579 | PubMed |
| 6 | 20162574 | miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. | Int J Cancer | 2010 | https://conductscience.org/library/papers/20162574 | PubMed |
| 7 | 12154352 | Live or let die: the cell's response to p53. | Nat Rev Cancer | 2002 | https://conductscience.org/library/papers/12154352 | PubMed |
| 8 | 12545155 | A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. | Oncogene | 2003 | https://conductscience.org/library/papers/12545155 | PubMed |
| 9 | 25651787 | Global cancer statistics, 2012. | CA Cancer J Clin | 2015 | https://conductscience.org/library/papers/25651787 | PubMed |
| 10 | 14744438 | MicroRNAs: genomics, biogenesis, mechanism, and function. | Cell | 2004 | https://conductscience.org/library/papers/14744438 | PubMed |
| 11 | 25674237 | High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer. | Int J Clin Exp Pathol | 2014 | https://conductscience.org/library/papers/25674237 | PubMed |
| 12 | 16141061 | Ribo-gnome: the big world of small RNAs. | Science | 2005 | https://conductscience.org/library/papers/16141061 | PubMed |
| 13 | 23178712 | miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. | FEBS Lett | 2013 | https://conductscience.org/library/papers/23178712 | PubMed |
| 14 | 24144591 | miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1. | Biochem Biophys Res Commun | 2013 | https://conductscience.org/library/papers/24144591 | PubMed |
| 15 | 28086946 | MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. | J Ovarian Res | 2017 | https://conductscience.org/library/papers/28086946 | PubMed |
| 16 | 11902585 | Multidrug resistance in cancer: role of ATP-dependent transporters. | Nat Rev Cancer | 2002 | https://conductscience.org/library/papers/11902585 | PubMed |
| 17 | 11099028 | Surfing the p53 network. | Nature | 2000 | https://conductscience.org/library/papers/11099028 | PubMed |
| 18 | 16918307 | Biomarkers and multiple drug resistance in breast cancer. | Curr Cancer Drug Targets | 2006 | https://conductscience.org/library/papers/16918307 | PubMed |
| 19 | 27362808 | miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. | Cell Death Dis | 2016 | https://conductscience.org/library/papers/27362808 | PubMed |
| 20 | 21471222 | Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21471222 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42802834 | Reduced Exosomal miR-22 Promotes Cisplatin Resistance and Migration in Non-Small Cell Lung Cancer Cells Through MDM4 Upregulation. | Onco Targets Ther | 2026 | https://conductscience.org/library/papers/42802834 | PubMed |
| 39849498 | Selective arm-usage of pre-miR-1307 dysregulates angiogenesis and affects breast cancer aggressiveness. | BMC Biol | 2025 | https://conductscience.org/library/papers/39849498 | PubMed |
| 39382427 | MicroRNA-1307-3p contributes to breast cancer progression through PRM2. | Thorac Cancer | 2024 | https://conductscience.org/library/papers/39382427 | PubMed |
| 35559394 | LncRNA TTN-AS1 confers tamoxifen resistance in breast cancer via sponging miR-107 to modulate PI3K/AKT signaling pathway. | Am J Transl Res | 2022 | https://conductscience.org/library/papers/35559394 | PubMed |
| 35456388 | MicroRNA Expression in Pseudoexfoliation Syndrome with the Use of Next-Generation Sequencing. | Genes (Basel) | 2022 | https://conductscience.org/library/papers/35456388 | PubMed |
| 35444536 | Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35444536 | PubMed |
| 35018230 | MDM4 alternative splicing and implication in MDM4 targeted cancer therapies. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/35018230 | PubMed |
| 34767243 | MiR-106b-5p Promotes Malignant Behaviors of Cervical Squamous Cell Carcinoma Cells by Targeting TIMP2. | Reprod Sci | 2022 | https://conductscience.org/library/papers/34767243 | PubMed |
| 34524579 | MicroRNAs as a clue to overcome breast cancer treatment resistance. | Cancer Metastasis Rev | 2022 | https://conductscience.org/library/papers/34524579 | PubMed |
| 33888565 | The roles and regulation of MDM2 and MDMX: it is not just about p53. | Genes Dev | 2021 | https://conductscience.org/library/papers/33888565 | PubMed |
| 33569931 | Breast Ultrasound Microvascular Imaging and Radiogenomics. | Korean J Radiol | 2021 | https://conductscience.org/library/papers/33569931 | PubMed |
| 33507700 | Association between Genetic Polymorphisms of miR-1307, miR- 1269, miR-3117 and Breast Cancer Risk in a Sample of South East Iranian Women. | Asian Pac J Cancer Prev | 2021 | https://conductscience.org/library/papers/33507700 | PubMed |
| 33084878 | Pyntacle: a parallel computing-enabled framework for large-scale network biology analysis. | Gigascience | 2020 | https://conductscience.org/library/papers/33084878 | PubMed |
| 33014864 | Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway. | Front Oncol | 2020 | https://conductscience.org/library/papers/33014864 | PubMed |
| 32811812 | The rs7911488-T allele promotes the growth and metastasis of colorectal cancer through modulating miR-1307/PRRX1. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/32811812 | PubMed |
| 32635183 | Identification of miRNA Master Regulators in Breast Cancer. | Cells | 2020 | https://conductscience.org/library/papers/32635183 | PubMed |
| 32309220 | Expressions of miR-21 and miR-210 in Breast Cancer and Their Predictive Values for Prognosis. | Iran J Public Health | 2020 | https://conductscience.org/library/papers/32309220 | PubMed |
| 31841993 | Nuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy. | Mol Ther Nucleic Acids | 2020 | https://conductscience.org/library/papers/31841993 | PubMed |
| 31402562 | miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. | Mol Oncol | 2019 | https://conductscience.org/library/papers/31402562 | PubMed |
| 30689920 | The long and the short of it: the MDM4 tail so far. | J Mol Cell Biol | 2019 | https://conductscience.org/library/papers/30689920 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29697201
GET https://conductscience.org/api/papers/v1/29697201/references?page=2